| Drug Type Proteolysis-targeting chimeras (PROTAC) | 
| Synonyms HDBNJ 2812, HDBNJ2812 | 
| Action degraders | 
| Mechanism EGFR C797S degraders(Epidermal Growth Factor Receptor C797S degraders), EGFR L858R degraders(EGFR exon 21 L858R mutation degraders), EGFR T790M degraders(Epidermal Growth Factor Receptor T790M degraders) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| EGFR C797S Mutation Non-small Cell Lung Cancer | Preclinical | South Korea  | 22 Mar 2024 | |
| EGFR C797S Mutation Non-small Cell Lung Cancer | Preclinical | South Korea  | 22 Mar 2024 | |
| EGFR C797S Mutation Non-small Cell Lung Cancer | Preclinical | South Korea  | 22 Mar 2024 | 





